WallStSmart

Cardiol Therapeutics Inc Class A (CRDL)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CRDL leads profitability with a 0.0% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).

CRDL

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -14.58

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRDL1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Market CapQuality
$55.95B9/10

Large-cap with strong market position

Areas to Watch

CRDL4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$141.78M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

TAK4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Free Cash FlowQuality
$-26.01B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CRDL

The strongest argument for CRDL centers on Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bear Case : CRDL

The primary concerns for CRDL are Revenue Growth, EPS Growth, Market Cap.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

CRDL profiles as a value stock while TAK is a turnaround play — different risk/reward profiles.

CRDL carries more volatility with a beta of 0.51 — expect wider price swings.

TAK is growing revenue faster at 3.9% — sustainability is the question.

CRDL generates stronger free cash flow (-8M), providing more financial flexibility.

Bottom Line

TAK scores higher overall (57/100 vs 17/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardiol Therapeutics Inc Class A

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?